Captab

Capecitabine

In combination w/ docetaxel for locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Monotherapy for locally advanced or metastatic breast cancer after failure of taxane & anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. In combination w/ lapatinib ditosylate for advanced or metastatic breast cancer whose tumors over express HER2 & who have received prior therapy including anthracycline, taxane & trastuzumab. Metastatic CRC. 1st-line treatment of advanced oesophagogastric cancer in combination w/ platinum-based regimen. Adjuvant treatment of patients following surgery of stage III (Duke's stage C) colon cancer.

Colon, breast & CRC Monotherapy: Initially 1,250 mg/m² bd (morning & evening) for 2 wk followed by 1-wk rest period. Combination therapy: Breast cancer In combination w/ docetaxel: Initially 1,250 mg/m² bd for 2 wk followed by 1-wk rest period & docetaxel 75 mg/m² as 1-hr IV infusion every 3 wk. In combination w/ lapatinib ditosylate: 2,000 mg/m² daily in 2 doses 12 hr apart for Day 1-14 in repeating 21-day cycle & lapatinib ditosylate 1,250 mg once daily from Day 1-21. Colon, CRC In combination w/ oxaliplatin &/or bevacizumab: 1,000 mg/m² bd for 2 wk followed by 1-wk rest period (1st dose given on evening of Day 1 & last dose on morning of Day 15) & bevacizumab 7.5 mg/kg IV infusion over 30-90 min followed by oxaliplatin 130 mg/m² IV infusion over 2 hr given as 3-wkly schedule on Day 1 every 3 wk. Adjuvant treatment w/ stage III colon cancer Duration: 6 mth. Gastric cancer In combination w/ platinum-based regimen: 1,000 mg/m² bd for 14 days followed by 1-wk rest period (1st dose given on evening of Day 1 & last dose on morning of Day 15). In combination w/ epirubicin: 625 mg/m² bd continuously & epirubicin 50 mg/m² as IV bolus in day 1 every 3 wk then cisplatin 60 mg/m² (triple regimen), 80 mg/m² (double regimen) or oxaliptin 130 mg/m² on day 1 as 2-hr IV infusion every 3 wk.

Should be taken with food: Swallow whole w/ water w/in 30 min after a meal. Do not crush/cut.

Hypersensitivity to capecitabine or fluorouracil. History of severe & unexpected reactions to fluoropyrimidine therapy. Known complete dihydropyrimidine dehydrogenase (DPD) deficiency. Severe leukopenia, neutropenia or thrombocytopenia. Recent or concomitant use w/ brivudine. Severe hepatic impairment & renal impairment (CrCl <30 mL/min). Pregnancy & lactation.

Discontinue use if severe skin reactions occur. Interrupt treatment if grade ≥2 dehydration, grade 2 or 3 hand-foot syndrome occur. Prior history of CAD, significant cardiac disease, arrhythmias & angina pectoris; preexisting hypo- or hypercalcaemia; central or peripheral nervous system disease eg, brain metastasis or neuropathy; DM or electrolyte disturbances; complete or partial dihydropyrimidine dehydrogenase deficiency. Monitor patients w/ severe diarrhoea & administer fluid & electrolyte replacement upon dehydration. Perform phenotype &/or genotype testing for DPD deficiency prior to therapy. Not to be administered concomitantly w/ brivudine. Closely monitor INR or prothrombin time in patients receiving oral coumarin-derivative anticoagulant therapy. Carefully monitor for ophthalmological complications eg, keratitis & corneal disorders. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Mild to moderate liver dysfunction. Moderate renal impairment. May affect ability to drive & use machines. Women of childbearing potential should use effective contraception during & for 6 mth after last dose. Male partners should use effective contraception during & for 3 mth after last dose. Childn & adolescents <18 yr. Elderly >60 yr.

Neutropenia, anaemia; paraesthesia, dysgeusia, headache; increased lacrimation; constipation, dyspepsia; alopecia, nail disorder; arthralgia, pain in extremity; pyrexia, lethargy; chest pain. Monotherapy: Anorexia; diarrhoea, vomiting, nausea, stomatitis, abdominal pain; palmar-plantar erythrodysaesthesia syndrome; fatigue, asthenia. Herpes viral infection, nasopharyngitis, lower resp tract infection; dehydration, decreased wt; insomnia, depression; dizziness; conjunctivitis, eye irritation; thrombophlebitis; dyspnoea, epistaxis, cough, rhinorrhoea; GI haemorrhage, constipation, upper abdominal pain, flatulence, dry mouth; hyperbilirubinemia; LFT abnormalities; rash, erythema, dry skin, pruritus, skin hyperpigmentation & desquamation, macular rash, dermatitis, pigmentation disorder; back pain; peripheral oedema, malaise. Combination therapy: Leucopenia, neutropenic fever, thrombocytopenia; decreased appetite; dysaesthesia, peripheral neuropathy & sensory neuropathy; lower limb oedema, HTN, embolism & thrombosis; sore throat, pharyngeal dysaesthesia; myalgia; weakness, temp intolerance. Herpes zoster, UTI, oral candidiasis, URTI, rhinitis, flu, infection, oral herpes; bone marrow depression, febrile neutropenia; hypersensitivity; hypokalaemia, hyponatraemia, hypomagnesaemia, hypocalcaemia, hyperglycaemia; sleep disorder, anxiety; neurotoxicity, tremor, neuralgia; hypersensitivity reaction, hypoaesthesia; visual disorders, dry eye, eye pain, visual impairment, blurred vision; tinnitus, hypoacusis; atrial fibrillation, cardiac ischaemia/infarction; flushing, hypotension, hypertensive crisis, hot flush, phlebitis; hiccups, pharyngolaryngeal pain, dysphonia; upper GI haemorrhage, mouth ulceration, gastritis, abdominal distension & discomfort, GERD, oral pain, dysaesthesia, paraesthesia & hypoaesthesia, dysphagia, rectal haemorrhage, lower abdominal pain, abnormal hepatic function; hyperhidrosis, erythematous rash, urticaria, night sweats; jaw pain, muscle spasms, trismus, muscular weakness; haematuria, proteinuria, decreased renal CrCl, dysuria; mucosal inflammation, pain, limb pain, chills, flu-like illness, fever, infusion-related reaction & site pain, inj site reaction & pain; contusion.

Increased toxicity w/ brivudine. Altered coagulation parameters &/or bleeding w/ coumarin-derivative anticoagulants eg, warfarin & phenprocoumon. Increased plasma conc of phenytoin. Enhanced toxicity w/ folinic/folic acid. Increased plasma conc w/ Al- & Mg hydroxide-containing antacid. Decreased absorption rate w/ food intake. Avoid concomitant use w/ allopurinol. Concomitant use w/ CYP2C9 substrates; interferon-α & RT.

Cytotoxic Chemotherapy

L01BC06 - capecitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.

B